Nurse Practitioner Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Cheri Monette

Nurse Practitioner, Gerontology Leeds, MA Nurse Practitioner

NPI 1649753005 CMS profile 11249234

38 Mulberry St Ste 204, Leeds, MA 01053

Open in the dashboard

General payments

$1,062

40 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cheri Monette of Leeds, MA is reported in the CMS Open Payments database as having received $1,062 across 40 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,032 39
2024 General $29 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cheri Monette
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Cheri Monette were reported at $1,032. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Cheri Monette Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $133 $44–$396 $132
2022 $0 $142 $48–$452 $149
2023 $0 $158 $53–$482 $160
2024 $29 $171 $55–$533 $164
2025 $1,032 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. E.R. Squibb & Sons, L.L.C. $266 7 payments
  2. Otsuka America Pharmaceutical, Inc. $231 10 payments
  3. Janssen Pharmaceuticals, Inc $189 7 payments
  4. AbbVie, Inc. $89 4 payments
  5. Alkermes, Inc. $67 3 payments
  6. Indivior Inc. $61 2 payments
  7. ITI, Inc. $42 2 payments
  8. Neurocrine Biosciences, Inc. $40 2 payments
  9. Lundbeck LLC $29 1 payment
  10. Axsome Therapeutics, Inc. $28 1 payment
  11. Other $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $1,062 40 payments
Products named General payments · program years 2024–2025
  1. COBENFY $266 7 payments
  2. SPRAVATO $189 7 payments
  3. REXULTI $187 7 payments
  4. VRAYLAR $89 4 payments
  5. LYBALVI $67 3 payments
  6. ARISTADA Cns $67 3 payments
  7. ARISTADA Cns $67 3 payments
  8. ARISTADA Cns $67 3 payments
  9. ARISTADA Cns $67 3 payments
  10. SUBLOCADE $61 2 payments
  11. Other $223 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

753

Median for Nurse Practitioner: 389

Drug cost

$34,990

Median for Nurse Practitioner: $21,885

Branded share of claims

14.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 57 $16,470
Divalproex Sodium Generic 41 $3,286
Gemtesa Vibegron Brand 12 $2,960
Quetiapine Fumarate Generic 51 $1,702
Gabapentin Generic 61 $1,380
Methenamine Hippurate Generic 11 $1,073
Escitalopram Oxalate Generic 27 $911
Famotidine Generic 39 $643
Tamsulosin Hcl Generic 17 $581
Tramadol Hcl Generic 33 $532

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$30,096

Medicare's payments for the services billed

Medicare patients

120

Average age 80

Services billed

488

85 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Alzheimer's or dementia 65%
Arthritis 63%
Depression 55%
Heart failure 33%
Chronic kidney disease 32%
Diabetes 26%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record